Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
EMBC logo EMBC
Upturn stock rating
EMBC logo

Embecta Corp (EMBC)

Upturn stock rating
$13.88
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

10/15/2025: EMBC (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $16.67

1 Year Target Price $16.67

Analysts Price Target For last 52 week
$16.67 Target price
52w Low $9.1
Current$13.88
52w High $20.58

Analysis of Past Performance

Type Stock
Historic Profit 18.2%
Avg. Invested days 32
Today’s Advisory PASS
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulation Last Close 10/15/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 800.66M USD
Price to earnings Ratio 9.64
1Y Target Price 16.67
Price to earnings Ratio 9.64
1Y Target Price 16.67
Volume (30-day avg) 5
Beta 1.07
52 Weeks Range 9.10 - 20.58
Updated Date 10/17/2025
52 Weeks Range 9.10 - 20.58
Updated Date 10/17/2025
Dividends yield (FY) 4.32%
Basic EPS (TTM) 1.42

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 7.58%
Operating Margin (TTM) 35.43%

Management Effectiveness

Return on Assets (TTM) 3.8%
Return on Equity (TTM) -

Valuation

Trailing PE 9.64
Forward PE -
Enterprise Value 2104197796
Price to Sales(TTM) 0.73
Enterprise Value 2104197796
Price to Sales(TTM) 0.73
Enterprise Value to Revenue 1.91
Enterprise Value to EBITDA 8.36
Shares Outstanding 58485119
Shares Floating 57239386
Shares Outstanding 58485119
Shares Floating 57239386
Percent Insiders 0.47
Percent Institutions 102.12

ai summary icon Upturn AI SWOT

Embecta Corp

stock logo

Company Overview

overview logo History and Background

Embecta Corp. was spun off from Becton, Dickinson and Company (BD) in April 2022. It focuses on diabetes care, specifically insulin delivery solutions.

business area logo Core Business Areas

  • Insulin Delivery: Embecta develops, manufactures, and sells a range of pen needles and syringes used by people with diabetes to inject insulin.

leadership logo Leadership and Structure

Devdatt (Dev) Kurdikar is the CEO. The company has a traditional corporate structure with various departments reporting to the executive team.

Top Products and Market Share

overview logo Key Offerings

  • Pen Needles: Embecta's pen needles are used with insulin pens for convenient and accurate insulin delivery. They are a leading player in this market with an estimated 25% market share. Competitors include Novo Nordisk, B. Braun, and HTL-Strefa.
  • Revenue: Revenues are over $1B
  • Insulin Syringes: Embecta's insulin syringes are used for traditional insulin delivery methods. Market share is approximately 20% of this product category. Competitors include B. Braun, Nipro, and Terumo.

Market Dynamics

industry overview logo Industry Overview

The diabetes care market is driven by the increasing prevalence of diabetes globally. The market is competitive, with established players and evolving technologies.

Positioning

Embecta is a leading pure-play diabetes care company focused on insulin delivery. Their competitive advantage lies in their established brand, extensive distribution network, and focus on quality and reliability.

Total Addressable Market (TAM)

The global diabetes market is estimated to be over $100 billion. Embecta is well-positioned to capture a significant share of the insulin delivery segment which is estimated at $4 Billion.

Upturn SWOT Analysis

Strengths

  • Leading market position in pen needles and syringes
  • Established brand reputation
  • Extensive global distribution network
  • Focus on quality and reliability

Weaknesses

  • Dependence on insulin delivery market
  • Limited product diversification
  • Vulnerable to technological disruptions (e.g., insulin pumps, continuous glucose monitors)
  • High debt load after spin-off

Opportunities

  • Expanding into emerging markets
  • Developing new insulin delivery technologies
  • Acquiring complementary businesses
  • Partnerships with insulin manufacturers

Threats

  • Increasing competition from established and new players
  • Technological advancements that reduce reliance on insulin injections
  • Pricing pressures from healthcare providers and payers
  • Regulatory changes impacting diabetes care

Competitors and Market Share

competitor logo Key Competitors

  • NVO
  • B Braun (Not Traded on US Exchange)

Competitive Landscape

Embecta competes primarily on brand recognition, product quality, and distribution network. Competitors offer a wider range of diabetes care products and services.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is tied to the overall growth of the diabetes market. Since spinning off from BD in April 2022 it has seen slow steady growth.

Future Projections: Future growth is projected to be in the low single digits, driven by emerging markets and new product innovations. Analyst estimates vary based on market conditions and company performance.

Recent Initiatives: Recent initiatives include cost-cutting measures, debt reduction, and expanding into new markets.

Summary

Embecta Corp is a major player in the insulin delivery market with strong brand recognition and distribution capabilities. Its high debt level from the spin-off and reliance on the pen needle and insulin syringe markets present challenges. Future success depends on successful debt reduction, cost management, and innovation in a competitive landscape. Embecta needs to look out for disruptuve technologies which can change the market share.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings
  • Analyst Reports
  • Industry Research Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor.

Upturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Embecta Corp

Exchange NASDAQ
Headquaters Parsippany, NJ, United States
IPO Launch date 2022-04-01
President, CEO & Director Mr. Devdatt Kurdikar Ph.D.
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 2100
Full time employees 2100

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.